Nasal tumours causing blockage and recurring infections: Both benign growths like polyps and more aggressive cancers such ... checked with a nasal endoscopy or imaging like MRI or CT scan. “Early ...

After RT, purulent nasal discharge, nasal congestion, and significant anosmia (16, 17) ultimately lead to nasal disease and low quality of life (9, 18, 19) in NPC patients (Figure 1). Numerous studies ...

CT angiography sensitivity ranged from 75.5–87.3%, while specificity held near 90% across scales. Sensitivity refers to how well a test finds its target, in this case, brain death.

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid ...

Paris and Tarrytown, NY, June 15, 2025. Sanofi and Regeneron Pharmaceuticals, Inc. today presented positive results from the EVEREST phase 4 study of adults with severe chronic rhinosinusitis with ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...

The final, formatted version of the article will be published soon. In the cohort, 81.5 % of specimens exceeded the ≥ 10 eosinophils•HPF-¹ threshold and more than half surpassed 55 eosinophils•HPF-¹ ...